Critical illness encephalopathy Dementia F03
Conditions
Interventions
Group 1: Patients who receive intensive care treatment and who obtain a value of >= 3,2 in the interview with a close relative/partner (IQCODE= Informant Questionnaire on Cognitive Decline in the Elde
Collection of data concerning vital signs, lab results, artificial respiration, events like surgery or complications and CNS-influencing medication over the course of the hospital stay (intensiv care
Collection of data concerning vital signs, lab results, artificial respiration, events like surgery or complications and CNS-influencing medication over the course of the hospital stay (intensiv care
Sponsors
Kurt-Goldstein-Institut, Privates Institut für Gesundheitsforschung
Eligibility
Sex/Gender
All
Age
30 Years to 90 Years
Inclusion criteria
Inclusion criteria: 1. Women and man between 30 and 90 years of age. 2. Treatment on either surgical and/or conservative intensive care unit 3. Written consent by the study participant or his/her authorized representative or verbal agreement in front of witnesses
Exclusion criteria
Exclusion criteria: 1. Acute neurological disease with cerebral involvement (stroke, traumatic-brain-injury, ect.). 2. Intensive care treatment >= 7 days within the last 2 years preceding the current hospitalization. 3. Pre-existing cognitive impairment due to other diagnosed diseases: Dementia (f.ex. Alzheimer’s Disease, other neurodegenerative diseases (f.ex. M.Parkinson), traumatic brain injury, epilepsia, subarachnoid hemorrhage, psychiatric disease, stroke within the last 6 months or with known cognitive impairment. 4. Interview with relatives not possible. 5. IQCODE result (obtained by interview with relatives) >= 3,9. 6. Nursing level >=2 (also application process) and/or institutionalized nursing care; exception: assisted living. 7. Pre-existing liver cirrhosis, pre-existing chronic kidney insufficiency with dialysis, pre-existing lung disease (f.ex. COPD) with home oxygen therapy, pre-existing malignant disease with ongoing chemotherapy. 8. Expectation not to survive the course of the study (One-Year-survival-probability < 50%). 9. Lack of ability to participate in the tests (f.ex. language barrier, impaired vigilance, muscle disease ect.). 10. Treatment for more than 48 hours on an intensive care unit of a non-participating hospital immediately preceding the current intensive care treatment .
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Scores from neuropsycholocial tests at day 0 (CERAD, Stroop: colour-word-interference test) | — |
Secondary
| Measure | Time frame |
|---|---|
| - Cognitive impairment after 9 months (according to the neuropsychological test scores: CERAD, Strooop: colour-word-interference test) - Newly diagnosed neurological disease (Dementia – defined by the CERAD test result after 9 months, idiopathic parkinsons-syndrom – measured by UPDRS III and diagnosed by outpatient neurologist) - Health-dependent quality of life (SF-36) - (Cognitive) functional status according to activity of daily life – measured by the Barthel-Index and IQCODE (interview with relatives) - Mental impairment (Hospital Anxiety and - Depression Scale - HADS) - Intrahospital Mortality - 9-Months Mortality | — |
Countries
Germany
Contacts
Public ContactJudith v.Hofen-Hohloch
Klink und Poliklinik für Neurologie, Universitätsklinikum Leipzig
Outcome results
None listed